OrbiMed Capital GP VII LLC — SEC insider filings
SEC reporting owner CIK 1760648. 73 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers the 50 most recent of 73 filings on record, filed 2022-05-05 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 55 legs across 17 filings — 15,573,032 shares, $111,030,210 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 79 legs across 23 filings — 6,295,251 shares, $96,723,750 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 80.
- Largest priced transaction: sale of 787,024 shares @ $45.38 ($35,715,149) in Enliven Therapeutics, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 5 | — | 8 legs · 2,174,831 sh · $74,560,296 | 4 |
| Electra Therapeutics, Inc. (ETRA) | Director, 10% owner | 3 | 18 legs · 1,898,020 sh · $24,349,642 | — | 8 |
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, 10% owner | 2 | 3 legs · 950,000 sh · $16,150,000 | — | 16 |
| Q32 Bio Inc. (QTTB) | Director, 10% owner | 1 | 2 legs · 1,875,000 sh · $15,000,000 | — | — |
| Aspen Neuroscience, Inc. (ASPE) | Director, 10% owner | 2 | 1 leg · 1,000,000 sh · $15,000,000 | — | 10 |
| MBX Biosciences, Inc. (MBX) | Director, 10% owner | 2 | 6 legs · 940,672 sh · $14,020,756 | — | 5 |
| Keros Therapeutics, Inc. (KROS) | Director | 2 | — | 2 legs · 250,000 sh · $11,002,500 | 2 |
| Terns Pharmaceuticals, Inc. (TERN) | Director, 10% owner | 3 | 4 legs · 3,827,931 sh · $9,929,800 | 6 legs · 56,164 sh · $561,640 | 3 |
| Kinnate Biopharma Inc. (KNTE) | Director, 10% owner | 4 | 14 legs · 2,866,100 sh · $7,760,135 | — | 7 |
| Arcutis Biotherapeutics, Inc. (ARQT) | 10% owner | 1 | — | 2 legs · 341,971 sh · $7,287,402 | — |
+6 more issuers among the filings shown — every filing appears in the table below.
Insider filings — OrbiMed Capital GP VII LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 9,816 @ $7.85 · Purchase (P): 39,600 @ $7.85 · Purchase (P): 4,000 @ $8.24 · Purchase (P): 16,000 @ $8.24 · Purchase (P): 20,700 @ $8.45 · Purchase (P): 2,000 @ $8.45 | EDGAR |
| 2026-11-05 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 24,313 @ $7.84 · Purchase (P): 97,800 @ $7.84 · Purchase (P): 24,400 @ $7.88 · Purchase (P): 98,600 @ $7.88 · Purchase (P): 9,267 @ $7.78 · Purchase (P): 37,100 @ $7.78 · +4 more | EDGAR |
| 2026-11-04 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ORBIMED ADVISORS LLC | Conversion (C): 196,541 · Conversion (C): 642,745 · Conversion (C): 616,984 · Conversion (C): 625,743 · Conversion (C): 507,119 · Purchase (P): 1,000,000 @ $15 · +5 more | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) jointly with ORBIMED ADVISORS LLC | Holdings only — no transactions reported | EDGAR |
| 2026-09-30 | 4 | ADARx Pharmaceuticals, Inc. (ADRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd, OrbiMed Genesis GP LLC | Conversion (C): 10,690,530 · Conversion (C): 2,000,962 · Conversion (C): 769,601 · Conversion (C): 564,187 · Purchase (P): 300,249 @ $17 · Conversion (C): 7,127,019 · +13 more | EDGAR |
| 2026-09-24 | 3 | ADARx Pharmaceuticals, Inc. (ADRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Holdings only — no transactions reported | EDGAR |
| 2026-09-23 | 4 | Electra Therapeutics, Inc. (ETRA) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Conversion (C): 2,002,310 · Conversion (C): 1,087,934 · Conversion (C): 1,703,314 · Purchase (P): 333,333 @ $15 · Conversion (C): 758,279 · Purchase (P): 1,000,000 @ $15 · +4 more | EDGAR |
| 2026-06-24 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 24,846 @ $45.38 · Sale (S): 1,477 @ $45 · Sale (S): 787,024 @ $45.38 · Sale (S): 46,776 @ $45 | EDGAR |
| 2026-06-17 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 9,086 @ $45.02 · Sale (S): 272,322 @ $45.02 | EDGAR |
| 2026-06-01 | 4 | Q32 Bio Inc. (QTTB) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-06-26 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 231,600 @ $0.35 · Sale (S): 138,800 @ $0.33 · Sale (S): 213,257 @ $0.33 | EDGAR |
| 2025-04-24 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 78,049 @ $0.34 · Sale (S): 89,328 @ $0.34 · Sale (S): 68,195 @ $0.32 | EDGAR |
| 2025-04-17 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 10,326 @ $0.38 · Sale (S): 61,638 @ $0.33 · Sale (S): 77,090 @ $0.33 | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-01-14 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 126,209 @ $0.66 · Sale (S): 17,986 @ $0.64 · Sale (S): 79,024 @ $0.60 | EDGAR |
| 2025-01-08 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 19,481 @ $0.77 · Sale (S): 52,536 @ $0.71 · Sale (S): 75,007 @ $0.68 | EDGAR |
| 2024-12-26 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 230,321 @ $0.60 | EDGAR |
| 2024-12-11 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 54,181 @ $0.84 · Sale (S): 8,015 @ $0.80 · Sale (S): 80 @ $0.80 | EDGAR |
| 2024-12-06 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 76,200 @ $0.79 · Sale (S): 20,903 @ $0.82 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Capital GP IX LLC | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-09-23 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 39,300 @ $0.71 | EDGAR |
| 2024-09-18 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Sale (S): 63,100 @ $0.74 · Sale (S): 111,400 @ $0.73 · Sale (S): 25,631 @ $0.73 | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-08-15 | 4 | Keros Therapeutics, Inc. (KROS) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 220,600 @ $44.01 · Sale (S): 29,400 @ $44.01 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) jointly with ORBIMED ADVISORS LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Ltd, OrbiMed Genesis GP LLC | Sale (S): 39,433 @ $10 · Sale (S): 5,401 @ $10 · Sale (S): 6,142 @ $10 · Sale (S): 4,009 @ $10 · Sale (S): 556 @ $10 · Sale (S): 623 @ $10 | EDGAR |
| 2024-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Sale (S): 33,300 @ $22.14 · Sale (S): 1,000,000 @ $22.14 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Code (U): 17,063,000 · Code (U): 650,600 | EDGAR |
| 2023-08-17 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 38,327 @ $0.75 · Sale (S): 248,819 @ $0.75 · Sale (S): 535,534 @ $0.75 | EDGAR |
| 2023-08-02 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 26,622 @ $3 · Sale (S): 29,700 @ $3 · Sale (S): 153,078 @ $3 | EDGAR |
| 2023-07-27 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 7,800 @ $2.92 · Sale (S): 4,700 @ $2.92 · Sale (S): 26,700 @ $2.92 | EDGAR |
| 2023-07-19 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 328,482 @ $3.05 · Purchase (P): 151,450 @ $3.05 | EDGAR |
| 2023-07-17 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 9,800 @ $2.40 · Sale (S): 52,800 @ $2.40 · Sale (S): 132,100 @ $2.40 | EDGAR |
| 2023-06-29 | 4 | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Purchase (P): 617,382 @ $0.84 · Purchase (P): 575,195 @ $0.84 | EDGAR |
| 2023-05-19 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Option exercise (M): 2,125 @ $4.28 · Option exercise (M): 2,125 (derivative) @ $0 | EDGAR |
| 2023-05-08 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Purchase (P): 83,459 @ $2.75 · Purchase (P): 312,991 @ $2.75 · Purchase (P): 83,459 @ $2.75 · Purchase (P): 490,512 @ $2.82 · Purchase (P): 490,511 @ $2.82 | EDGAR |
| 2023-05-02 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Purchase (P): 60,998 @ $2.55 · Purchase (P): 228,754 @ $2.55 · Purchase (P): 60,997 @ $2.55 · Purchase (P): 124,544 @ $2.62 · Purchase (P): 467,068 @ $2.62 · Purchase (P): 124,545 @ $2.62 · +3 more | EDGAR |
| 2023-04-17 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 703 @ $1.82 · Sale (S): 3,784 @ $1.82 · Sale (S): 9,459 @ $1.82 · Sale (S): 2,091 @ $1.86 · Sale (S): 11,245 @ $1.86 · Sale (S): 28,110 @ $1.86 · +3 more | EDGAR |
| 2023-04-12 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 2,584 @ $1.79 · Sale (S): 13,899 @ $1.79 · Sale (S): 34,745 @ $1.79 · Sale (S): 703 @ $1.82 · Sale (S): 3,784 @ $1.82 · Sale (S): 9,459 @ $1.82 · +3 more | EDGAR |
| 2023-04-07 | 4 | Galecto, Inc. (GLTO) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC, OrbiMed Israel GP II, L.P., OrbiMed Advisors Israel II Ltd | Sale (S): 4,687 @ $2.18 · Sale (S): 25,220 @ $2.18 · Sale (S): 63,058 @ $2.18 · Sale (S): 487 @ $2 · Sale (S): 2,620 @ $2 · Sale (S): 6,558 @ $2 | EDGAR |
| 2023-02-27 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Grant/award (A): 7,611,458 · Grant/award (A): 288,114 | EDGAR |
| 2023-02-23 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Grant/award (A): 550,000 · Grant/award (A): 550,000 | EDGAR |
| 2022-12-28 | 4 | Terns Pharmaceuticals, Inc. (TERN) jointly with ORBIMED ADVISORS LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Ltd, OrbiMed Genesis GP LLC | Purchase (P): 137,931 @ $7.25 | EDGAR |
| 2022-11-09 | 4 | Theseus Pharmaceuticals, Inc. (THRX) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 192,000 @ $5.21 | EDGAR |
| 2022-09-21 | 4 | Third Harmonic Bio, Inc. (THRD) jointly with ORBIMED ADVISORS LLC | Conversion (C): 5,479,071 · Purchase (P): 300,000 @ $17 · Conversion (C): 8,593,750 (derivative) · Conversion (C): 2,441,407 (derivative) · Conversion (C): 1,342,065 (derivative) | EDGAR |
| 2022-08-18 | 4 | Terns Pharmaceuticals, Inc. (TERN) jointly with ORBIMED ADVISORS LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Ltd, OrbiMed Genesis GP LLC | Purchase (P): 2,470,200 @ $2.42 · Purchase (P): 457,400 @ $2.42 · Purchase (P): 762,400 @ $2.42 · Purchase (P): 207,500 (derivative) · Purchase (P): 38,450 (derivative) · Purchase (P): 64,050 (derivative) | EDGAR |
| 2022-07-01 | 4 | Sierra Oncology, Inc. (SRRA) jointly with ORBIMED ADVISORS LLC, ORBIMED CAPITAL LLC, OrbiMed Genesis GP LLC | Disposition to issuer (D): 1,511,362 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 226,704 @ $55 · Disposition to issuer (D): 1,136,250 (derivative) @ $0 · Disposition to issuer (D): 170,437 (derivative) @ $0 · Disposition to issuer (D): 170,437 (derivative) @ $0 | EDGAR |
| 2022-06-28 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) jointly with ORBIMED ADVISORS LLC, ORBIMED CAPITAL LLC | Sale (S): 306,027 @ $21.31 · Sale (S): 35,944 @ $21.31 | EDGAR |
| 2022-05-05 | 4/A | Passage BIO, Inc. (PASG) jointly with ORBIMED ADVISORS LLC | Purchase (P): 50,800 @ $5 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1760648 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs